HOME >> MEDICINE >> NEWS
WHO Director-General To Speak On Tobacco, WHO Reform

Washington, DC, March 15, 1999- Dr. Gro Harlem Brundtland, Director-General of the World Health Organization, will give two major speeches during her visit to Washington this week.

The first is a keynote address on Thursday, March 18 on "The Tobacco Epidemic: A threat to the World's Children," at the International Policy Conference on Children and Tobacco, being held at the Organization of American States.

The second is a Morning Newsmaker event on Friday, March 19 at the National Press Club on the World Health Organization's reform process and the impact of U.S. payment policy.

Below are details of the events:

Thursday, March 18, 1999, 9:15 a.m., Hall of the Americas, Organization of American States, 17th Street and Constitution Ave, NW: Dr. G.H. Brundtland to give Keynote Address at the International Policy Conference on Children and Tobacco on "The Tobacco Epidemic: A threat to the World's Children." Press Availability with Dr. Brundtland after speech, from 9:30 to 10 a.m.

Friday, March 19, 1999, 9 a.m., cNational Press Club - 529 14th St. NW, 13th Floor : Dr. G. H. Brundtland Morning Newsmaker breakfast: Description: Dr. Gro Harlem Brundtland, the director-general of the World Health Organization, will discuss the organization's reform and the impact of U.S. payment policy.

During her visit to Washington, Dr. Brundtland will also meet with Secretary of State Madeleine Albright, U.S. Senators Richard J. Durbin, Ron Wyden, and Susan Collins, co-sponsors of the conference on children and tobacco; members of the House Appropriations Committee, and Tim Wirth, President of the U.N. Foundation.

For further information contact: Daniel Epstein, (listed above)
Or
Ambassador Tom Loftus, tel 202-331-9081, WHO Liaison Office, email WHOLofus@aol.com


'"/>

Contact: Daniel Epstein
epsteind@paho.org
202-974-3459
Pan American Health Organization
15-Mar-1999


Page: 1

Related medicine news :

1. Speakers cramp, a new type of involuntary mouth-, lip-muscle movement
2. Media Advisory: Surgeon General To Speak
3. Forum Urges Medicare Reform To Emphasize Health Promotion

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: WHO Director General Speak Tobacco WHO Reform

(Date:5/22/2013)... WEDNESDAY, May 22 (HealthDay News) -- Roughly four in ... obstructive pulmonary disease (COPD) actually do not have the ... issue: Faulty diagnoses were made based on an evaluation ... "gold standard" disease test known as spirometry, which shows ... the amount of air they can exhale and how ...
(Date:5/22/2013)... New research from Brigham and Women,s Hospital (BWH) finds ... uncommon but deadly lung disease, may be effective in ... findings will be presented at the American Thoracic Society ... New England Journal of Medicine on May 22 ... edition., "While this variant of the MUC5B gene is ...
(Date:5/22/2013)... ATS 2013, PHILADELPHIA ─More than 40 percent of ... funded clinic did not have the disease, researchers ... diagnostic "gold standard" for chronic obstructive pulmonary disease. ... the under-diagnosis of COPD, there has not been ... of over-diagnosis," said Christian Ghattas, MD., MSc, ...
(Date:5/22/2013)... In the past decade, more ... courts with donated uniforms, shoes, balls and other ... to partnering with manufacturers to provide youth with sporting ... $8.8 million in sports and fitness equipment over 10 ... outfitted for physical activity. , An inaugural donation ...
(Date:5/22/2013)... Alabama (PRWEB) May 22, 2013 ... solutions to state Health and Human Services and ... of Mental Health (ADMH) selected the CoCENTRIX ... platform to manage the Health Records and coordinate ... psychiatric hospitals. , CoCENTRIX is transitioning the ...
Breaking Medicine News(10 mins):Health News:COPD May Be Over-Diagnosed Among Uninsured 2Health News:Genetic marker associated with risk for pulmonary fibrosis 2Health News:Study finds COPD is over-diagnosed among uninsured patients 2Health News:Study finds COPD is over-diagnosed among uninsured patients 3Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 2Health News:Good Sports celebrates 10-year anniversary with major milestone: 500,000 American kids equipped for physical activity 3Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 2Health News:The State of Alabama Selects the CoCENTRIX Coordinated Care Platform to Facilitate Care for Its Citizens Treated in State Psychiatric Hospitals 3
(Date:5/22/2013)... 22, 2013  Grifols, a global healthcare company based ... from a study demonstrating that a higher dose of ... levels of the alpha 1 protein in patients ... are considered within the normal range for healthy individuals. ... low levels of the alpha 1 proteinase inhibitor ...
(Date:5/22/2013)...  BD (Becton, Dickinson and Company) (NYSE: ... today the publication of its 2012 Sustainability Report ... continues to focus on the Company,s shared value approach ... of shared value — creating value for shareholders by ... are fundamental to our strategy," said Vincent ...
(Date:5/22/2013)... Calif. , May 22, 2013 Rigel ... the clinical advancement of three programs in development. The ... a JAK/SYK inhibitor, R348, being developed by Rigel as ... programs are aimed at oncology targets and are being ... under development by BerGenBio AS (BerGenBio) and a ligase ...
Breaking Medicine Technology:Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 2Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 3Rigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye 4
Cached News: